Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 368

1.

Descriptive comparison of hospital formulary decisions with published oncology valuation methods.

Lam SW, Siebenaller C, Earl M, Hill BT, Kalaycio M, Rini B, Carraway HE, Leonard M, Sekeres MA.

J Oncol Pharm Pract. 2019 Oct 9:1078155219877927. doi: 10.1177/1078155219877927. [Epub ahead of print]

PMID:
31594520
2.

Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years.

Borate U, Norris BA, Statler A, Fu R, Bucy T, Sekeres MA.

Blood Adv. 2019 Sep 24;3(18):2738-2747. doi: 10.1182/bloodadvances.2019000293.

3.

Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials.

Cortes JE, Dombret H, Merchant A, Tauchi T, DiRienzo CG, Sleight B, Zhang X, Leip EP, Shaik N, Bell T, Chan G, Sekeres MA.

Future Oncol. 2019 Sep 13. doi: 10.2217/fon-2019-0373. [Epub ahead of print]

4.

A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.

Yalniz FF, Berdeja JG, Maris MB, Lyons RM, Reeves JA Jr, Essell JH, Patel P, Sekeres M, Hughes A, Mappa S, Garcia-Manero G.

Br J Haematol. 2019 Aug 29. doi: 10.1111/bjh.16173. [Epub ahead of print]

PMID:
31468521
5.

Leukemia evolving from paroxysmal nocturnal hemoglobinuria.

Awada H, Rahman S, Durrani J, Asad MF, Kerr CM, Adema V, Kishtagari A, Graham A, Snider CA, Kongkiatkamon S, Nagata Y, Patel BJ, Carraway HE, Sekeres MA, Maciejewski JP, Visconte V.

Leukemia. 2019 Aug 20. doi: 10.1038/s41375-019-0555-0. [Epub ahead of print] No abstract available.

PMID:
31431736
6.

Genomics of therapy-related myeloid neoplasms.

Kuzmanovic T, Patel BJ, Sanikommu SR, Nagata Y, Awada H, Kerr CM, Przychodzen BP, Jha BK, Hiwase D, Singhal D, Advani AS, Nazha A, Gerds AT, Carraway HE, Sekeres MA, Mukherjee S, Maciejewski JP, Radivoyevitch T.

Haematologica. 2019 Aug 14. pii: haematol.2019.219352. doi: 10.3324/haematol.2019.219352. [Epub ahead of print]

7.

The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine.

Nawrocki ST, Han Y, Visconte V, Przychodzen B, Espitia CM, Phillips J, Anwer F, Advani A, Carraway HE, Kelly KR, Sekeres MA, Maciejewski JP, Carew JS.

Leukemia. 2019 Jul 29. doi: 10.1038/s41375-019-0529-2. [Epub ahead of print] No abstract available.

PMID:
31358855
8.

Distinct clinical and biological implications of CUX1 in myeloid neoplasms.

Aly M, Ramdzan ZM, Nagata Y, Balasubramanian SK, Hosono N, Makishima H, Visconte V, Kuzmanovic T, Adema V, Nazha A, Przychodzen BP, Kerr CM, Sekeres MA, Abazeed ME, Nepveu A, Maciejewski JP.

Blood Adv. 2019 Jul 23;3(14):2164-2178. doi: 10.1182/bloodadvances.2018028423.

9.

The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.

Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK.

Leuk Lymphoma. 2019 May 21:1-11. doi: 10.1080/10428194.2019.1616186. [Epub ahead of print]

PMID:
31111762
10.

A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.

Advani AS, Cooper B, Visconte V, Elson P, Chan R, Carew J, Wei W, Mukherjee S, Gerds A, Carraway H, Nazha A, Hamilton B, Sobecks R, Caimi P, Tomlinson B, Malek E, Little J, Miron A, Pink J, Maciejewski J, Unger A, Kalaycio M, de Lima M, Sekeres MA.

Clin Cancer Res. 2019 Jul 15;25(14):4231-4237. doi: 10.1158/1078-0432.CCR-18-3886. Epub 2019 Apr 16.

PMID:
30992301
11.

NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy.

Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, Patel K, Ganan-Gomez I, Jabbour E, Kadia T, Ravandi F, DiNardo C, Borthakur G, Takahashi K, Konopleva M, Komrokji RS, DeZern A, Kuzmanovic T, Maciejewski J, Pierce S, Colla S, Sekeres MA, Kantarjian H, Bueso-Ramos C, Garcia-Manero G.

Blood Adv. 2019 Mar 26;3(6):922-933. doi: 10.1182/bloodadvances.2018026989.

12.

Subclonal STAT3 mutations solidify clonal dominance.

Kerr CM, Clemente MJ, Chomczynski PW, Przychodzen B, Nagata Y, Adema V, Visconte V, Lichtin AE, Mustjoki S, Radivoyevitch T, Sekeres MA, Maciejewski JP.

Blood Adv. 2019 Mar 26;3(6):917-921. doi: 10.1182/bloodadvances.2018027862.

13.

Impact of germline CTC1 alterations on telomere length in acquired bone marrow failure.

Shen W, Kerr CM, Przychozen B, Mahfouz RZ, LaFramboise T, Nagata Y, Hanna R, Radivoyevitch T, Nazha A, Sekeres MA, Maciejewski JP.

Br J Haematol. 2019 Jun;185(5):935-939. doi: 10.1111/bjh.15862. Epub 2019 Mar 19.

PMID:
30891747
14.

Wilms tumor 1 expression: addressing the 'elephant' in MDS.

Madanat YF, Sekeres MA.

Leuk Lymphoma. 2019 Mar;60(3):566-567. doi: 10.1080/10428194.2018.1516882. Epub 2019 Feb 4. No abstract available.

PMID:
30714447
15.

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.

Awada H, Nagata Y, Goyal A, Asad MF, Patel B, Hirsch CM, Kuzmanovic T, Guan Y, Przychodzen BP, Aly M, Adema V, Shen W, Williams L, Nazha A, Abazeed ME, Sekeres MA, Radivoyevitch T, Haferlach T, Jha BK, Visconte V, Maciejewski JP.

Blood Adv. 2019 Feb 12;3(3):339-349. doi: 10.1182/bloodadvances.2018024216.

16.

Rethinking clinical trial endpoints in myelodysplastic syndromes.

Sekeres MA, Steensma DP.

Leukemia. 2019 Mar;33(3):570-575. doi: 10.1038/s41375-018-0367-7. Epub 2019 Jan 30. Review.

PMID:
30700839
17.

Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.

Hamilton BK, Rybicki L, Hirsch C, Przychodzen B, Nazha A, Gerds AT, Hanna R, Kalaycio M, Sekeres MA, Sobecks R, de Lima M, Majhail NS, Maciejewski J.

Bone Marrow Transplant. 2019 Aug;54(8):1281-1286. doi: 10.1038/s41409-019-0444-1. Epub 2019 Jan 17.

PMID:
30655603
18.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

19.

BCOR and BCORL1 mutations in myelodysplastic syndromes (MDS): clonal architecture and impact on outcomes.

Abuhadra N, Mukherjee S, Al-Issa K, Adema V, Hirsch CM, Advani A, Przychodzen B, Makhoul A, Awada H, Maciejewski JP, Sekeres MA, Nazha A.

Leuk Lymphoma. 2019 Jun;60(6):1587-1590. doi: 10.1080/10428194.2018.1543885. Epub 2019 Jan 8. No abstract available.

PMID:
30618304
20.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S.

Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.

Supplemental Content

Loading ...
Support Center